MENLO PARK, Calif., May 9 /PRNewswire-FirstCall/ -- XTENT, Inc. today announced that 6-month follow-up data from the CUSTOM II trial will be presented at EuroPCR, taking place May 22 to 25 in Barcelona. The company will also hold an analyst teleconference to review the CUSTOM II data following the late-breaking data session; host a symposium on drug eluting stents and novel approaches to multi-lesion and long lesion stenting; and transmit a live case from Onze Lieve Vrouw (OLV) Hospital in Aalst, Belgium during the conference. XTENT will also present its latest innovations at booth G9 in the exhibition hall.
Schedule of Events Tuesday, May 22
Time/Location: 4:30-6:40p.m. CEST/10:30-12:40p.m. EDT (CUSTOM II Presentation: 6:11-6:17p.m. CEST/12:11-12:17p.m. EDT); Main Arena, Room 1, Barcelona International Convention Center (CCIB)
Event: CUSTOM II Early Results, Late Breaking Coronary Trial Presentation: Prof. Eberhard Grube, MD, chief of cardiology at the Siegburg Heart Center and principal investigator of the CUSTOM II clinical trial, will present six-month follow-up data from the CUSTOM II trial evaluating use of the Custom NX(R) Drug Eluting Stent (DES) System in patients with long or multiple coronary lesions.
Time: 8:00p.m. CEST/ 2:00p.m. EDT
Event: Analyst Briefing. XTENT will host an analyst webcast and telebriefing to review the CUSTOM II data presented during the late breaking coronary trials session. The teleconference can be accessed via the investor relations section of the Company’s website at http://investor.xtentinc.com/events.cfm or by calling 800-361-0912 (from the U.S.), 913-981-5559 (international). Please dial in or access the website 5 to 10 minutes prior to the beginning of the call. The webcast will be archived on the website for a minimum of three months, and can be accessed at the investor relations portion of the company’s website at http://investor.xtentinc.com
Wednesday, May 23
Time/Location: 12:00p.m. CEST; Room 6, CCIB
Event: Symposium on Customizable drug-eluting stents: A novel approach to multi-lesion and long lesion stenting. XTENT will host a symposium, chaired by Bernard de Bruyne, M.D. Ph.D, Cardiovascular Center, OLV Hospital, Aalst, Belgium. The symposium will feature presentations by Martin Leon, M.D. (Multi- lesion and long lesion stenting: challenges and key considerations); Pieter Stella, M.D. (XTENT Custom NX: technical overview); Andrew Carter, D.O. (XTENT Custom NX: pre-clinical overview); Prof. Eberhard Grube, M.D. (XTENT CUSTOM clinical programme); and CUSTOM I and II Investigators (A new approach to multi-lesion and long lesions).
Thursday, May 24
Time/Location: 9:30-10:25a.m. CEST, Room 5, CCIB
Event: Live case transmission from OLV Hospital, Aalst, Belgium. The live case transmission, with Bernard de Bruyne, M.D. Ph.D, will occur during the 8:00a.m to 12:00p.m. CEST session titled “Glimpse into the future - The parade of the next generation of new coronary drug-eluting stents,” chaired by Patrick Serruys, M.D.
About XTENT
XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT(R) Custom NX(R) DES Systems have not been approved for sale by any regulatory authority.
Information about XTENT is available at our website at http://www.xtentinc.com.
XTENT, Inc.
CONTACT: investors, Tim Kahlenberg, Chief Financial Officer of XTENT,+1-650-475-9400, or tkahlenberg@xtentinc.com; or media, Danielle Bertrand,+1-415-946-1056, or dbertrand@weisscommpartners.com, for XTENT
Web site: http://www.xtentinc.com//
